Thesis
MRD diagnostics growing 33% YoY; separation into two public companies is the make-or-break value unlock
clonoSEQ, Adaptive's FDA-cleared blood cancer minimal residual disease test, is compounding at 33% revenue growth with 36,111 tests delivered in Q2 2026 alone. The thesis resolves on whether separating the MRD business from the loss-generating Immune Medicine unit surfaces standalone value — or whether the spin strands Immune Medicine without support. The structural risk is that $345M in zero-coupon convertible debt, layered onto $39.8M quarterly burn, constrains both entities post-separation if MRD growth decelerates.
Focus
Planned separation of MRD and Immune Medicine businesses into two independent public companies
2027
Bull
If the MRD business trades as a standalone oncology diagnostics compounder at peer-level revenue multiples, the sum-of-parts valuation could substantially exceed the current blended multiple; clonoSEQ volume growth of 43% YoY in Q2 2026 and raised full-year guidance demonstrate the underlying commercial momentum that would underpin that re-rating. A clean separation also allows Immune Medicine to pursue its own partnership or strategic alternatives unconstrained by the MRD growth story.
Bear
Separation execution carries meaningful operational and tax complexity, and the timeline could slip into 2027 or beyond, leaving investors in a prolonged holding pattern while convertible note dilution overhang weighs on the share price. If MRD growth decelerates or reimbursement pressures emerge in hematologic malignancies, the standalone multiple compression could offset any conglomerate-discount relief.
Unlock the full thesis for ADPT.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialGenerated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.